Abstract
Publications on the design, synthesis, pharmacological research, and clinical trials of the Russian original class III antiarrhythmic drugs nibentan {(RS)-4-nitro-N-[1-phenyl-5-(diethylamino)pentyl]benzamide hydrochloride} and niferidyl {4-nitro-N-[(1RS)-1-(4-fluorophenyl)-2-(1-ethylpiperidin-4-yl)ethyl]benzamide hydrochloride}are reviewed.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
